AIMS: To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users. DESIGN: A generalized estimating equation model assuming a binomial distribution and a logit-link function was used to examine for a possible protective effect of MMT use on HCV incidence. SETTING: Data from three prospective cohort studies of illicit drug users in Vancouver, Canada between 1996 and 2012. PARTICIPANTS: A total of 1004 HCV antibody-negative illicit drug users stratified by exposure to MMT. MEASUREMENTS: Baseline and semi-annual HCV antibody testing and standardized interviewer-administered questionnaire soliciting self-reported data relating to drug use patterns, risk behaviors, detailed socio-demographic data and status of active participation in an MMT program. FINDINGS: One hundred and eighty-four HCV seroconversions were observed for an HCV incidence density of 6.32 [95% confidence interval (CI) = 5.44-7.31] per 100 person-years. After adjusting for potential confounders, MMT exposure was protective against HCV seroconversion [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29-0.76]. In subanalyses, a dose-response protective effect of increasing MMT exposure on HCV incidence (AOR = 0.87; 95% CI = 0.78-0.97) per increasing 6-month period exposed to MMT was observed. CONCLUSION: Participation in methadone maintenance treatment appears to be highly protective against hepatitis C incidence among illicit drug users. There appears to be a dose-response protective effect of increasing methadone exposure on hepatitis C incidence.
AIMS: To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users. DESIGN: A generalized estimating equation model assuming a binomial distribution and a logit-link function was used to examine for a possible protective effect of MMT use on HCV incidence. SETTING: Data from three prospective cohort studies of illicit drug users in Vancouver, Canada between 1996 and 2012. PARTICIPANTS: A total of 1004 HCV antibody-negative illicit drug users stratified by exposure to MMT. MEASUREMENTS: Baseline and semi-annual HCV antibody testing and standardized interviewer-administered questionnaire soliciting self-reported data relating to drug use patterns, risk behaviors, detailed socio-demographic data and status of active participation in an MMT program. FINDINGS: One hundred and eighty-four HCV seroconversions were observed for an HCV incidence density of 6.32 [95% confidence interval (CI) = 5.44-7.31] per 100 person-years. After adjusting for potential confounders, MMT exposure was protective against HCV seroconversion [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29-0.76]. In subanalyses, a dose-response protective effect of increasing MMT exposure on HCV incidence (AOR = 0.87; 95% CI = 0.78-0.97) per increasing 6-month period exposed to MMT was observed. CONCLUSION: Participation in methadone maintenance treatment appears to be highly protective against hepatitis C incidence among illicit drug users. There appears to be a dose-response protective effect of increasing methadone exposure on hepatitis C incidence.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali Journal: J Gen Intern Med Date: 2005-12-07 Impact factor: 5.128
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: N Craine; M Hickman; J V Parry; J Smith; A M Walker; D Russell; B Nix; M May; T McDonald; M Lyons Journal: Epidemiol Infect Date: 2009-02-19 Impact factor: 2.451
Authors: Ryan McNeil; Thomas Kerr; Solanna Anderson; Lisa Maher; Chereece Keewatin; M J Milloy; Evan Wood; Will Small Journal: Soc Sci Med Date: 2015-04-07 Impact factor: 4.634
Authors: B Jacka; B C Bray; T L Applegate; B D L Marshall; V D Lima; K Hayashi; K DeBeck; J Raghwani; P R Harrigan; M Krajden; J S G Montaner; J Grebely Journal: J Viral Hepat Date: 2017-09-04 Impact factor: 3.728
Authors: T Spelman; M D Morris; G Zang; T Rice; K Page; L Maher; A Lloyd; J Grebely; G J Dore; A Y Kim; N H Shoukry; M Hellard; J Bruneau Journal: J Epidemiol Community Health Date: 2015-03-26 Impact factor: 3.710
Authors: Evan B Cunningham; Brendan Jacka; Kora DeBeck; Tanya L Applegate; P Richard Harrigan; Mel Krajden; Brandon D L Marshall; Julio Montaner; Viviane Dias Lima; Andrea D Olmstead; M-J Milloy; Evan Wood; Jason Grebely Journal: Drug Alcohol Depend Date: 2015-04-20 Impact factor: 4.492
Authors: Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17